Despite social media buzz, Ozempic is not a quick-fix weight loss solution, doctors say | Canada News Media
Connect with us

Media

Despite social media buzz, Ozempic is not a quick-fix weight loss solution, doctors say

Published

 on

Kerry Toneguzzi has tried everything to lose weight.

From low-calorie and liquid diets to Weight Watchers, nothing worked. In 2007, she had bariatric surgery and lost 100 pounds — only to gain it all back.

When she was diagnosed with diabetes in the fall of 2020, her doctor suggested she try Ozempic — a drug approved in Canada to treat diabetes, with a frequent side effect of weight loss.

“In the beginning, I didn’t think it would ever work for me because nothing really had worked for me,” Toneguzzi, 55, said.

But it did. The Ottawa-area insurance underwriter lost 115 pounds over about two years. What she finds even more remarkable is that she hasn’t gained any of it back.

“For me to maintain my weight for a year, it’s a win,” she said. “This drug has given me a second chance at life.”

 

 

Ozempic for weight loss: What’s known about the potential and the risks

 

Questions are swirling around the use of semaglutide, commonly sold under the brand name Ozempic, for weight loss. CBC’s Christine Birak explores the risks and benefits of off-label uses of the drug, which is traditionally used to treat Type 2 diabetes.

Demand has risen steadily

Like Toneguzzi, many Canadian obesity specialists and endocrinologists are welcoming Ozempic as a drug that actually works in treating what they say is a genetic, medical condition.

“We’ve failed to have success in pharmacotherapy until now,” said Dr. Sean Wharton, an internal medicine specialist who runs a weight and diabetes management clinic in Burlington, Ont.

With the advent of Ozempic, people living with obesity finally have a drug that can make a difference and can be an alternative to bariatric surgery, he said.

But Ozempic has gained notoriety in recent months, with celebrities singing the drug’s praises and many people posting success stories in weight loss they attribute to the drug.

This photograph taken on Feb. 23, 2023, in Paris, shows the anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk.” (Joel Saget/AFP/Getty Images)

Demand for Ozempic in Canada has risen steadily over the last year, according to the Neighbourhood Pharmacy Association of Canada, which represents most of the major pharmacy chains in Canada, as well as many community drugstores.

The problem with that, some doctors and pharmacists say, is that Ozempic isn’t intended for patients who want to drop a few pounds of “cosmetic weight.”  Plus, people who need Ozempic likely need it for life. Studies have shown that once they stop taking it, the weight often comes back.

“[There] should be no question about that. Nobody should think that they’re using this for short term and going to stop it,” Wharton said.

“This is a forever medication because [obesity is] a genetic disease.”

We’ve been hearing a lot about Ozempic recently. It’s a drug to treat diabetes, but it’s now becoming popular with celebrities and regular folks wanting to shed a few pounds. Dr. Ali Zentner, a Vancouver-based specialist in internal medicine, diabetes and obesity, shares what you should know about the drug.

A disease, not cosmetic

Ozempic costs between $200 and $300 per month in Canada. Its manufacturer, Novo Nordisk, also got Health Canada approval in 2021 for a drug called Wegovy. Ozempic and Wegovy have the identical active ingredient — semaglutide — but Wegovy is a higher dose to specifically treat obesity.

Health Canada has also approved Wegovy for people who are overweight and also suffering from a serious weight-related condition such as hypertension, diabetes or obstructive sleep apnea.

Semaglutide works by acting like a hormone called glucagon-like peptide-1 (GLP-1), which promotes insulin production and also stimulates part of the brain that controls appetite. Patients take it by injection once a week.

Because Wegovy is not yet available in Canada — and Novo Nordisk has not given a date when it will be — some doctors are prescribing Ozempic at higher doses for their patients suffering from obesity.

Dr. Ehud Ur, an endocrinologist at St. Paul’s Hospital and Vancouver General Hospital, said it’s important to look at Ozempic and Wegovy as a medical solution to treat a life-threatening medical condition, in conjunction with changes to diet, exercise and sleep habits.

“Most people don’t understand that obesity is not a cosmetic problem. It’s a significant disease. People with obesity will have a 10, 15, 20-year reduction in their life expectancy because of their weight problems,” said Ur.

‘Asking for the drug’

But on the front lines of primary care, family doctors have been fielding a growing number of pleas from patients who want an Ozempic prescription, even though they’re not suffering from obesity, said Dr. Iris Gorfinkel, a family physician in Toronto.

“People who are coming to me as a family doctor are people who, you know, they’re struggling with the belly fat, they’re not even diabetic, they’re not even pre-diabetic and they’re asking for the drug,” she said.

Shelita Dattani, vice-president of pharmacy affairs for the Neighbourhood Pharmacy Association of Canada, also practices on a family health team that is dealing with patients looking for Ozempic as a “quick fix” for weight loss.

“I’ve had people ask me, I’ve had friends ask me … ‘you know, I have a wedding coming up’ or ‘I need to be in a bikini’ or whatever it is,” Dattani said.

Gorfinkel and Dattani both say those requests require thoughtful conversations with patients about weight loss and other measures they can take.

“Obesity is a holistic problem. It is a biopsychosocial problem,” Gorfinkel said.

Those conversations take a lot longer than just saying yes and writing a prescription, she said. Gorfinkel also worries about potential side effects.

Serious potential side effects

According to Novo Nordisk’s Ozempic information website, the most common side effects include nausea, vomiting, diarrhea, constipation and abdominal pain.

Those symptoms go away after a few weeks, said Ur. The website also lists more serious potential side effects including inflammation of the pancreas, gallbladder problems, kidney problems and low blood sugar.

It also notes that studies in rats showed thyroid tumours. Both Ur and Wharton said there’s no reason to believe that would happen in humans.

The health risks of living with obesity often outweigh the potential risks of taking the drug, they said.

“It’s important to understand who are the appropriate patients to treat because not everyone is a candidate for Ozempic,” Ur said.

“The simple point to make is that in any treatment in medicine you’re balancing risk against benefit.”

LISTEN | Use of Ozempic to treat obesity prompts both excitement and concern:

The Current19:40Use of Ozempic to treat obesity prompts both excitement and concern

The diabetes drug Ozempic has been hailed as an effective treatment for obesity, but there are concerns about whether publicity around the drug fuels harmful ideas around weight loss and diet culture. Matt Galloway talks to Dr. Ali Zentner, an internal medicine, diabetes and obesity specialist with Revolution Medical Clinic in Vancouver; and Eva Pila, an assistant professor and principal investigator at Western University’s Body Image and Health Research Lab.

Gorfinkel said she would consider prescribing Ozempic along with lifestyle changes if the patient met the medical criteria for obesity.

But so far, that hasn’t happened.

“I have yet to prescribe it to any patients,” Gorfinkel said.

“I’m extremely skeptical. I worry tremendously that if I do prescribe it what may happen is that when they come off of it, they may experience significant weight gain.”

‘Not a miracle’

When asked if Ozempic and Wegovy are meant to be taken for the rest of patients’ lives, Novo Nordisk Canada said in an email “just like other chronic diseases, type 2 diabetes and obesity both require long-term management.”

“Decisions about the appropriateness and duration of any medication should be made on an individual basis in consultation with a health-care professional,” spokeswoman Amy Snow said.

Toneguzzi, who has started a Facebook group in Ottawa for others who are considering Ozempic, has no illusions that the drug is anything short of a lifelong commitment to help maintain her weight.

She also wants to help others be realistic in their expectations, noting that along with taking Ozempic, she worked hard on her weight loss, including a “very regimented” approach to her diet.

“It’s not a miracle,” she said.

“It wasn’t just the medication. I had to change my complete lifestyle.”

Source link

Continue Reading

Media

What to stream this weekend: ‘Civil War,’ Snow Patrol, ‘How to Die Alone,’ ‘Tulsa King’ and ‘Uglies’

Published

 on

 

Hallmark launching a streaming service with two new original series, and Bill Skarsgård out for revenge in “Boy Kills World” are some of the new television, films, music and games headed to a device near you.

Also among the streaming offerings worth your time as selected by The Associated Press’ entertainment journalists: Alex Garland’s “Civil War” starring Kirsten Dunst, Natasha Rothwell’s heartfelt comedy for Hulu called “How to Die Alone” and Sylvester Stallone’s second season of “Tulsa King” debuts.

NEW MOVIES TO STREAM SEPT. 9-15

Alex Garland’s “Civil War” is finally making its debut on MAX on Friday. The film stars Kirsten Dunst as a veteran photojournalist covering a violent war that’s divided America; She reluctantly allows an aspiring photographer, played by Cailee Spaeny, to tag along as she, an editor (Stephen McKinley Henderson) and a reporter (Wagner Moura) make the dangerous journey to Washington, D.C., to interview the president (Nick Offerman), a blustery, rising despot who has given himself a third term, taken to attacking his citizens and shut himself off from the press. In my review, I called it a bellowing and haunting experience; Smart and thought-provoking with great performances. It’s well worth a watch.

— Joey King stars in Netflix’s adaptation of Scott Westerfeld’s “Uglies,” about a future society in which everyone is required to have beautifying cosmetic surgery at age 16. Streaming on Friday, McG directed the film, in which King’s character inadvertently finds herself in the midst of an uprising against the status quo. “Outer Banks” star Chase Stokes plays King’s best friend.

— Bill Skarsgård is out for revenge against the woman (Famke Janssen) who killed his family in “Boy Kills World,” coming to Hulu on Friday. Moritz Mohr directed the ultra-violent film, of which Variety critic Owen Gleiberman wrote: “It’s a depraved vision, yet I got caught up in its kick-ass revenge-horror pizzazz, its disreputable commitment to what it was doing.”

AP Film Writer Lindsey Bahr

NEW MUSIC TO STREAM SEPT. 9-15

— The year was 2006. Snow Patrol, the Northern Irish-Scottish alternative rock band, released an album, “Eyes Open,” producing the biggest hit of their career: “Chasing Cars.” A lot has happened in the time since — three, soon to be four quality full-length albums, to be exact. On Friday, the band will release “The Forest Is the Path,” their first new album in seven years. Anthemic pop-rock is the name of the game across songs of love and loss, like “All,”“The Beginning” and “This Is the Sound Of Your Voice.”

— For fans of raucous guitar music, Jordan Peele’s 2022 sci-fi thriller, “NOPE,” provided a surprising, if tiny, thrill. One of the leads, Emerald “Em” Haywood portrayed by Keke Palmer, rocks a Jesus Lizard shirt. (Also featured through the film: Rage Against the Machine, Wipers, Mr Bungle, Butthole Surfers and Earth band shirts.) The Austin noise rock band are a less than obvious pick, having been signed to the legendary Touch and Go Records and having stopped releasing new albums in 1998. That changes on Friday the 13th, when “Rack” arrives. And for those curious: The Jesus Lizard’s intensity never went away.

AP Music Writer Maria Sherman

NEW SHOWS TO STREAM SEPT. 9-15

— Hallmark launched a streaming service called Hallmark+ on Tuesday with two new original series, the scripted drama “The Chicken Sisters” and unscripted series “Celebrations with Lacey Chabert.” If you’re a Hallmark holiday movies fan, you know Chabert. She’s starred in more than 30 of their films and many are holiday themed. Off camera, Chabert has a passion for throwing parties and entertaining. In “Celebrations,” deserving people are surprised with a bash in their honor — planned with Chabert’s help. “The Chicken Sisters” stars Schuyler Fisk, Wendie Malick and Lea Thompson in a show about employees at rival chicken restaurants in a small town. The eight-episode series is based on a novel of the same name.

Natasha Rothwell of “Insecure” and “The White Lotus” fame created and stars in a new heartfelt comedy for Hulu called “How to Die Alone.” She plays Mel, a broke, go-along-to-get-along, single, airport employee who, after a near-death experience, makes the conscious decision to take risks and pursue her dreams. Rothwell has been working on the series for the past eight years and described it to The AP as “the most vulnerable piece of art I’ve ever put into the world.” Like Mel, Rothwell had to learn to bet on herself to make the show she wanted to make. “In the Venn diagram of me and Mel, there’s significant overlap,” said Rothwell. It premieres Friday on Hulu.

— Shailene Woodley, DeWanda Wise and Betty Gilpin star in a new drama for Starz called “Three Women,” about entrepreneur Sloane, homemaker Lina and student Maggie who are each stepping into their power and making life-changing decisions. They’re interviewed by a writer named Gia (Woodley.) The series is based on a 2019 best-selling book of the same name by Lisa Taddeo. “Three Women” premieres Friday on Starz.

— Sylvester Stallone’s second season of “Tulsa King” debuts Sunday on Paramount+. Stallone plays Dwight Manfredi, a mafia boss who was recently released from prison after serving 25 years. He’s sent to Tulsa to set up a new crime syndicate. The series is created by Taylor Sheridan of “Yellowstone” fame.

Alicia Rancilio

NEW VIDEO GAMES TO PLAY

— One thing about the title of Focus Entertainment’s Warhammer 40,000: Space Marine 2 — you know exactly what you’re in for. You are Demetrian Titus, a genetically enhanced brute sent into battle against the Tyranids, an insectoid species with an insatiable craving for human flesh. You have a rocket-powered suit of armor and an arsenal of ridiculous weapons like the “Chainsword,” the “Thunderhammer” and the “Melta Rifle,” so what could go wrong? Besides the squishy single-player mode, there are cooperative missions and six-vs.-six free-for-alls. You can suit up now on PlayStation 5, Xbox X/S or PC.

— Likewise, Wild Bastards isn’t exactly the kind of title that’s going to attract fans of, say, Animal Crossing. It’s another sci-fi shooter, but the protagonists are a gang of 13 varmints — aliens and androids included — who are on the run from the law. Each outlaw has a distinctive set of weapons and special powers: Sarge, for example, is a robot with horse genes, while Billy the Squid is … well, you get the idea. Australian studio Blue Manchu developed the 2019 cult hit Void Bastards, and this Wild-West-in-space spinoff has the same snarky humor and vibrant, neon-drenched cartoon look. Saddle up on PlayStation 5, Xbox X/S, Nintendo Switch or PC.

Lou Kesten

Source link

Continue Reading

Media

Trump could cash out his DJT stock within weeks. Here’s what happens if he sells

Published

 on

Former President Donald Trump is on the brink of a significant financial decision that could have far-reaching implications for both his personal wealth and the future of his fledgling social media company, Trump Media & Technology Group (TMTG). As the lockup period on his shares in TMTG, which owns Truth Social, nears its end, Trump could soon be free to sell his substantial stake in the company. However, the potential payday, which makes up a large portion of his net worth, comes with considerable risks for Trump and his supporters.

Trump’s stake in TMTG comprises nearly 59% of the company, amounting to 114,750,000 shares. As of now, this holding is valued at approximately $2.6 billion. These shares are currently under a lockup agreement, a common feature of initial public offerings (IPOs), designed to prevent company insiders from immediately selling their shares and potentially destabilizing the stock. The lockup, which began after TMTG’s merger with a special purpose acquisition company (SPAC), is set to expire on September 25, though it could end earlier if certain conditions are met.

Should Trump decide to sell his shares after the lockup expires, the market could respond in unpredictable ways. The sale of a substantial number of shares by a major stakeholder like Trump could flood the market, potentially driving down the stock price. Daniel Bradley, a finance professor at the University of South Florida, suggests that the market might react negatively to such a large sale, particularly if there aren’t enough buyers to absorb the supply. This could lead to a sharp decline in the stock’s value, impacting both Trump’s personal wealth and the company’s market standing.

Moreover, Trump’s involvement in Truth Social has been a key driver of investor interest. The platform, marketed as a free speech alternative to mainstream social media, has attracted a loyal user base largely due to Trump’s presence. If Trump were to sell his stake, it might signal a lack of confidence in the company, potentially shaking investor confidence and further depressing the stock price.

Trump’s decision is also influenced by his ongoing legal battles, which have already cost him over $100 million in legal fees. Selling his shares could provide a significant financial boost, helping him cover these mounting expenses. However, this move could also have political ramifications, especially as he continues his bid for the Republican nomination in the 2024 presidential race.

Trump Media’s success is closely tied to Trump’s political fortunes. The company’s stock has shown volatility in response to developments in the presidential race, with Trump’s chances of winning having a direct impact on the stock’s value. If Trump sells his stake, it could be interpreted as a lack of confidence in his own political future, potentially undermining both his campaign and the company’s prospects.

Truth Social, the flagship product of TMTG, has faced challenges in generating traffic and advertising revenue, especially compared to established social media giants like X (formerly Twitter) and Facebook. Despite this, the company’s valuation has remained high, fueled by investor speculation on Trump’s political future. If Trump remains in the race and manages to secure the presidency, the value of his shares could increase. Conversely, any missteps on the campaign trail could have the opposite effect, further destabilizing the stock.

As the lockup period comes to an end, Trump faces a critical decision that could shape the future of both his personal finances and Truth Social. Whether he chooses to hold onto his shares or cash out, the outcome will likely have significant consequences for the company, its investors, and Trump’s political aspirations.

Source link

Continue Reading

Media

Arizona man accused of social media threats to Trump is arrested

Published

 on

Cochise County, AZ — Law enforcement officials in Arizona have apprehended Ronald Lee Syvrud, a 66-year-old resident of Cochise County, after a manhunt was launched following alleged death threats he made against former President Donald Trump. The threats reportedly surfaced in social media posts over the past two weeks, as Trump visited the US-Mexico border in Cochise County on Thursday.

Syvrud, who hails from Benson, Arizona, located about 50 miles southeast of Tucson, was captured by the Cochise County Sheriff’s Office on Thursday afternoon. The Sheriff’s Office confirmed his arrest, stating, “This subject has been taken into custody without incident.”

In addition to the alleged threats against Trump, Syvrud is wanted for multiple offences, including failure to register as a sex offender. He also faces several warrants in both Wisconsin and Arizona, including charges for driving under the influence and a felony hit-and-run.

The timing of the arrest coincided with Trump’s visit to Cochise County, where he toured the US-Mexico border. During his visit, Trump addressed the ongoing border issues and criticized his political rival, Democratic presidential nominee Kamala Harris, for what he described as lax immigration policies. When asked by reporters about the ongoing manhunt for Syvrud, Trump responded, “No, I have not heard that, but I am not that surprised and the reason is because I want to do things that are very bad for the bad guys.”

This incident marks the latest in a series of threats against political figures during the current election cycle. Just earlier this month, a 66-year-old Virginia man was arrested on suspicion of making death threats against Vice President Kamala Harris and other public officials.

Continue Reading

Trending

Exit mobile version